Navigation Links
MaxLife Fund Corp. retains the Law firm, Anslow & Jaclin, LLP of Manalapan, N.J., to review MaxLife Fund Corp. options to be listed on the NASDAQ Capital Market
Date:10/5/2007

NEW JERSEY, Oct. 5 /PRNewswire-FirstCall/ - MaxLife Fund Corp. (OTC:MXFD), announced today that they have retained the law firm of Anslow & Jaclin, LLP to review the company options to be listed on the NASDAQ Capital Market.

The Company believes that listing on the NASDAQ Capital Market will provide greater visibility for our operations, and will vastly improve the flow of information to our shareholders and potential investors.

MaxLife Fund Corp. is a fund designated to excel in the Life Settlement sector and to partner with revenue generating businesses that are profitable, in the health sector. MaxLife is committed to create value for its shareholders by becoming one of the leading funds in the life and health sector.

Cautionary Statement Pursuant to Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:

This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this news release.

For further information contact:

MaxLife Fund Corp.

1-866-752-5557


'/>"/>
SOURCE MaxLife Fund Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Oracle Corp. to help build worlds first "Digital Hospital"
2. The Memory Retains Things that We Have forgotten
3. FDA may speed review of new drugs
4. Scientists review SARS
5. US Reviews Risks Of Tamiflu After 12 Children Die
6. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
7. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
8. A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm
9. Thumbs up in weight loss for vegetarian diets: scientific review
10. FDA Accords Priority Review For Pediatric Crohns Disease Drug
11. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:CVS Joins Retail Push for Non-Toxic Personal Care Products 2Health News:CVS Joins Retail Push for Non-Toxic Personal Care Products 3Health News:The Female Health Company Schedules Second Quarter Conference Call for May 14, 2008 2Health News:AIDS.gov Goes 2.0: Government HIV/AIDS Website Now Features a Blog, Podcasts, and More 2Health News:Hunger Hormone Makes Food Look More Tasty 2Health News:Hunger Hormone Makes Food Look More Tasty 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 2Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 4Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 5Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 6Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 7Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 2Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 3Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 4Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 5
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 1Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 1Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 3Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 4
Other Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8